Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03610516
Other study ID # CCFZ533X2202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 12, 2018
Est. completion date June 29, 2023

Study information

Verified date July 2023
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic efficacy of multiple doses of CFZ533 anti-CD40 monoclonal antibody in patients with moderately active lupus nephritis.


Description:

This was a randomized, subject and investigator blind, placebo controlled multicenter study with multiple doses of CFZ533 administered by 1-hour intravenous infusion over a 24 week treatment period, as compared to matched placebo infusion. The treatment period was followed by a 24-week safety follow-up period.The duration of the study (including the screening period) for each patient was approximately 53 weeks. The investigational drug or placebo was administered on top of standard of care therapy for lupus nephritis. Patients were screened within 29 days of the first study drug infusion. Eligibility was confirmed at the baseline visit within one week before the first dose. Eligible patients were assigned a randomization number and receive the intravenous infusion within 3 days of baseline visit.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date June 29, 2023
Est. primary completion date June 29, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Key Inclusion Criteria: - Men and women with systemic lupus erythematosus (SLE) aged = 18 years and = 75 years at screening, fulfilling at least 4 out of 11 criteria for SLE as defined by the American College of Rheumatology (Tan at al 1982, revised by Hochberg 1997) - Subjects must have a body mass index (BMI) within the range of 18 - 40 kg/m2 at screening visit - Histological diagnosis of proliferative lupus nephritis World Health Organization (WHO) ISN/RPS (Weening et al 2004) Class III or IV within 5 years of screening - Presence of antinuclear autoantibody (ANA titer = 1:80) at screening - Morning UPCR = 0.5 at screening visit and baseline visit - At least one of the following: 1. low complement level (C3 ? 0.9 g/L) or (C4 ? 0.1 g/L), and/or 2. elevated anti-dsDNA (= 30 IU/mL), and/or 3. urine sediment consistent with active proliferative LN such as presence of cellular (granular or red blood cell) casts or hematuria ( ?5 red blood cells per high power field) if other causes such as menstrual bleeding are excluded - Patient must have sufficient kidney function as estimated by eGFR ? 30mL/min/1.73 m2 at screening and baseline visits (Levey et al 2009) - Patient must have active disease as defined by proteinuria and additional symptoms as above despite standard of care therapy for LN as considered appropriate by the treating physician (e.g., corticosteroids and/or immunosuppressive or immunomodulatory treatments such as mycophenolate, azathioprine, methotrexate or hydroxychloroquine). For guidance, see published guidelines such as Bertsias et all 2012 and Hahn et al 2012. - Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must use highly effective methods of contraception during dosing and until study completion. Key Exclusion Criteria: - Any glomerulonephritis other than WHO Class III or IV lupus nephritis. Patients with proliferative nephritis (Class III or IV) who, in addition, have overlapping histological signs for other glomerulonephritis, e.g., Class V, are eligible at the investigatorĀ“s discretion. - Hypoalbuminemia (serum albumin of less than 2.0 g/dL) - Patients who have received: 1. oral or i.v. cyclophosphamide within 3 months prior to randomization 2. i.v. corticosteroid bolus (dose ? 1 mg/kg) within 3 months prior to randomization 3. rituximab or other B cell depleting agent within 12 months. for patients who received such treatment earlier, B cell count should be within normal ranges prior to randomization 4. belimumab within 6 months prior to randomization 5. any other biologic drug or an investigational drug within one months or five times the half-life, whichever is longer prior to randomization 6. any calcineurin inhibitor (e.g., tacrolimus or cyclosporin A) within 3 months prior to randomization - Patients who are at significant risk for the thromboembolic events based on the following: 1. history of either thrombosis or 3 or more spontaneous abortions 2. presence of lupus anticoagulant or prolonged activated partial thromboplastin time (aPTT) and no prophylactic treatment with aspirin or anticoagulants as per local standard of care - Have had signs or symptoms of a clinically significant systemic viral, bacterial or fungal infection within 30 days prior to randomization - Live vaccines within 4 weeks of the first study drug infusion Other protocol-defined inclusion/exclusion criteria may apply. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CFZ533
multiple doses of CFZ533 intravenous infusion
Placebo
multiple doses of placebo intravenous infusion

Locations

Country Name City State
Argentina Novartis Investigative Site Ciudad Autonoma de Bs As Buenos Aires
Argentina Novartis Investigative Site Cordoba
China Novartis Investigative Site Beijing
China Novartis Investigative Site Changsha Hunan
China Novartis Investigative Site Guangzhou Guangdong
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Urumqi Xinjiang
Germany Novartis Investigative Site Mainz
Hong Kong Novartis Investigative Site HongKong
Hungary Novartis Investigative Site Debrecen
Korea, Republic of Novartis Investigative Site Seoul Seocho Gu
Korea, Republic of Novartis Investigative Site Seoul
Russian Federation Novartis Investigative Site Rostov on Don
Russian Federation Novartis Investigative Site St-Petersburg
Russian Federation Novartis Investigative Site St. Petersburg
Russian Federation Novartis Investigative Site Yaroslavl
Taiwan Novartis Investigative Site Taichung
Taiwan Novartis Investigative Site Taichung
Taiwan Novartis Investigative Site Taipei
Tunisia Novartis Investigative Site Tunis
Turkey Novartis Investigative Site Kocaeli

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Argentina,  China,  Germany,  Hong Kong,  Hungary,  Korea, Republic of,  Russian Federation,  Taiwan,  Tunisia,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety as assessed by adverse events Number and percentage of patients with adverse events From baseline to week 49
Primary Renal proteinuria Ratio from baseline in urinary protein creatinine ratio (UPCR) to week 25 From baseline to week 25
Secondary Urine protein creatinine ratio (UPCR) and hematuria and cellular casts Ratio from baseline for urine protein creatinine ratio (UPCR) and hematuria and cellular casts to evaluate the renal effect. From baseline to week 49
Secondary Plasma pharmacokinetics (PK) of CFZ533: the area under plasma concentration-time curve calculated to the last quantifiable concentration point (AUClast). The following PK parameter will be determined from the plasma concentration time profile of CFZ533:
AUClast: AUClast is the area under plasma concentration-time curve calculated to the last quantifiable concentration point.
From baseline to week 49, pre dose and 1 hour post dose
Secondary Complete renal remission Proportion of patients who fulfill the criteria for complete renal remission according to ACR recommendation From baseline to week 49
Secondary Plasma pharmacokinetics (PK) of CFZ533: The observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval (Cthrough) Cthrough: The observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval From baseline to week 49, pre dose and 1 hour post dose
Secondary Plasma pharmacokinetics (PK) of CFZ533: The observed maximum plasma concentration following drug administration at steady state (Cmax,ss) Cmax,ss: The observed maximum plasma (or serum or blood) concentration following drug administration at steady state [mass/volume] From baseline to week 49, pre dose and 1 hour post dose
Secondary Plasma pharmacokinetics (PK) of CFZ533 The lowest plasma concentration observed during a dosing interval at steady state (Cmin,ss) Cmin,ss: The lowest plasma (or serum or blood) concentration observed during a dosing interval at steady state [mass/volume] From baseline to week 49, pre dose and 1 hour post dose
Secondary Total soluble CD40 concentrations Total soluble CD40 concentrations in plasma From baseline to week 49
Secondary Immunogenicity of CFZ533 Incidence of ADA-positive patients From baseline to week 49
See also
  Status Clinical Trial Phase
Recruiting NCT02936375 - The Iguratimod Effect on Lupus Nephritis (IGeLU) Phase 2
Completed NCT03597464 - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin Phase 3
Recruiting NCT01226147 - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis Phase 2
Completed NCT01206569 - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Phase 4
Active, not recruiting NCT00569101 - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis Phase 2
Terminated NCT00368264 - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Phase 2/Phase 3
Completed NCT00371319 - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Phase 4
Completed NCT00298506 - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V) N/A
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Terminated NCT04376827 - A Study of Guselkumab in Participants With Active Lupus Nephritis Phase 2
Recruiting NCT03526042 - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis N/A
Withdrawn NCT03859570 - Pentoxifylline in Lupus Nephritis Phase 4
Completed NCT03664908 - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)? N/A
Completed NCT01085097 - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis Phase 2
Active, not recruiting NCT05704088 - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT06429800 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis Phase 1
Recruiting NCT02226341 - ACTHar in the Treatment of Lupus Nephritis Phase 4
Recruiting NCT02453997 - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis N/A
Completed NCT01470183 - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients N/A
Terminated NCT00089804 - Study of LJP 394 in Lupus Patients With History of Renal Disease Phase 3